Descripción de la empresa
Autonomix Medical, Inc. operates as a development stage medical device company dedicated to advancing technologies for sensing and treating disorders related to the peripheral nervous system. The firm utilizes a proprietary technology platform that incorporates a catheter-based microchip-enabled sensing array designed to detect and differentiate specific physiological signals. This entity functions within the broader Healthcare sector, specifically targeting the Medical Devices industry, a space characterized by high regulatory hurdles and significant research and development expenditures. With a market capitalization of $4.33 million and an employee base consisting of eight individuals, the company represents a micro-cap entity with limited operational scale. These valuation figures and headcount suggest that the firm is in an early-stage development phase, where resources are primarily allocated to product advancement rather than commercial scaling, resulting in a small market presence relative to established industry peers.
Salud financiera
The company reports N/A for trailing twelve-month revenue and a net income of $-17,240,000, while EBITDA stands at $-17,492,000. The substantial gap between revenue and net income, compounded by the negative EBITDA, reveals a cost structure dominated by operational expenses and research costs that currently exceed all generated sales, a typical characteristic of development stage firms. Free cash flow is reported at $-5,933,875, indicating that the company is burning through capital reserves to fund its growth initiatives and technological development. Despite this cash outflow, the balance sheet holds $9.93 million in cash, which provides a buffer to sustain operations without immediate external financing. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting that the company has not yet achieved profitability or generated significant gross sales to cover its cost of goods sold. The firm carries N/A in total debt, and with a debt-to-equity ratio also listed as N/A, the capital structure relies almost exclusively on equity financing and cash reserves. The current ratio is 6.18, a figure that indicates strong short-term liquidity, suggesting the company possesses ample current assets to cover its current liabilities without risk of insolvency. Return on Equity is -188.7% and Return on Assets is -99.0%, metrics that reveal the company is currently destroying shareholder value and utilizing assets inefficiently in terms of generating profit, a common but risky state for pre-revenue medical device companies.
Evaluación de valoración
The trailing P/E ratio is N/A due to the lack of net income, while the forward P/E is listed at -0.05, a metric that implies the market is pricing in future earnings growth that has not yet materialized in historical financials. The price-to-book ratio stands at 0.51, indicating that the stock trades at a significant discount to its book value, which often occurs with speculative assets that have intangible value not fully captured on the balance sheet. The price-to-sales ratio is N/A because there is no reported revenue, and the EV/EBITDA is 0.32, a metric that suggests a valuation based on enterprise value relative to earnings before interest, taxes, depreciation, and amortization is extremely low due to the negative earnings base. Over the past year, the stock has traded between a 52-week low of $0.34 and a 52-week high of $2.82, showing a wide trading range typical of low liquidity micro-cap stocks. The beta value is -2.46, a highly unusual negative figure that indicates the stock's price movements are inversely correlated with the broader market and exhibit extreme volatility relative to the market index.
Growth & Income
Revenue growth year-over-year is N/A as there is no historical revenue data available to calculate a growth rate, and earnings growth year-over-year is also N/A for similar reasons. Since the company has not generated positive earnings, the comparison between earnings growth and revenue growth is not applicable, and the firm is not currently growing profits faster than revenue because it is not profitable. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning no dividends are distributed to shareholders. Instead of paying dividends, the company reinvests its limited cash reserves and any future earnings into its research and development efforts to advance its peripheral nervous system sensing technologies. The overall growth and income profile is characterized by a complete absence of current profitability or dividend income, relying entirely on the successful commercialization of its catheter-based microchip-enabled sensing array to transition from a cash-burning stage to a revenue-generating stage.